Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins: The known and the unknown

Pharmacogenomics

Volumn 13, Issue 3, 2012, Pages 323-341

  Lymperopoulos, Anastasios ^a   Bathgate, Ashley ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

adrenergic receptor; arrestin; G protein coupled receptor; GRK; heptahelical receptor; pharmacogenetics; phosphorylation; polymorphism; receptor desensitization; receptor downregulation; seven transmembrane spanning receptor; signal transduction

Indexed keywords

ADRENERGIC RECEPTOR; ARGININE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; G PROTEIN COUPLED RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 4; G PROTEIN COUPLED RECEPTOR KINASE 5; GLUTAMIC ACID; GLYCINE; GUANINE NUCLEOTIDE BINDING PROTEIN; MU OPIATE RECEPTOR; PROPRANOLOL; RETINA S ANTIGEN; RHO FACTOR; RHODOPSIN; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; VASOPRESSIN V2 RECEPTOR;

AFRICAN AMERICAN; CARDIOVASCULAR DISEASE; DEPRESSION; ENZYME PHOSPHORYLATION; GENE DELETION; GENETIC POLYMORPHISM; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HUMAN; INTERNALIZATION; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ARRESTINS; G-PROTEIN-COUPLED RECEPTOR KINASES; GTP-BINDING PROTEINS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SIGNAL TRANSDUCTION;

EID: 84856739717     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.178     Document Type: Review

References (123)

1. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 409(6822), 860-921 (2001). (Pubitemid 32165345)
2. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 291(5507), 1304-1351 (2001). (Pubitemid 32173090)
3. Flower DR. Modeling G-protein-coupled receptors for drug design. Biochem. Biophys. Acta 1422(3), 207-234 (1999). (Pubitemid 29512378)
4. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 53(1), 1-24 (2001). (Pubitemid 32173106)
5. Luttrell LM, Gesty-Palmer D. Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol. Rev. 62(2), 305-330 (2010).
6. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9(5), 373-386 (2010).
7. Lefkowitz RJ. Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol. Sci. 25(8), 413-422 (2004). (Pubitemid 38981557)
8. Johnson JA, Liggett SB. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin. Pharmacol. Ther. 89(3), 366-378 (2011).
9. Dorn GW 2nd. Adrenergic signaling polymorphisms and their impact on cardiovascular disease. Physiol. Rev. 90(3), 1013-1062 (2010).
10. Insel PA, Tang CM, Hahntow I, Michel MC. Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targets. Biochim. Biophys. Acta 1768(4), 994-1005 (2007). (Pubitemid 46452544)
11. Tang CM, Insel PA. Genetic variation in G-protein-coupled receptors-consequences for G-protein-coupled receptors as drug targets. Expert Opin. Ther. Targets 9(6), 1247-1265 (2005). (Pubitemid 41762877)
12. Johnson JA, Lima JJ. Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges. Pharmacogenetics 13(9), 525-534 (2003). (Pubitemid 37159631)
13. Sadee W, Hoeg E, Lucas J, Wang D. Genetic variations in human G protein-coupled receptors: implications for drug therapy. AAPS PharmSci. 3(3), E22 (2001).
14. Rana BK, Shiina T, Insel PA. Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 41, 593-624 (2001). (Pubitemid 32385900)
15. Dorn J. GRK mythology: G-protein receptor kinases in cardiovascular disease. J. Mol. Med. 87(5), 455-463 (2009).
16. Schoneberg T. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol. Ther. 104(3), 173-206 (2004). (Pubitemid 39531926)
17. Rosskopf D, Michel MC. Pharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicine. Pharmacol. Rev. 60(4), 513-535 (2008).
18. Stoffel RH 3rd, Pitcher JA, Lefkowitz RJ. Targeting G protein-coupled receptor kinases to their receptor substrates. J. Membr. Biol. 157(1), 1-8 (1997). (Pubitemid 27214509)
19. Pitcher JA, Touhara K, Payne ES, Lefkowitz RJ. Pleckstrin homology domain-mediated membrane association and activation of the beta-adrenergic receptor kinase requires coordinate interaction with G beta gamma subunits and lipid. J. Biol. Chem. 270(20), 11707-11710 (1995).
20. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 415(6868), 206-212 (2002). (Pubitemid 34059526)
21. Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu. Rev. Biochem. 67, 653-692 (1998). (Pubitemid 28411141)
22. Gurevich VV, Gurevich EV. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol. Ther. 110(3), 465-502 (2006).
23. Shukla AK, Violin JD, Whalen EJ, Gesty-Palmer D, Shenoy SK, Lefkowitz RJ. Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. Proc. Natl Acad. Sci. USA 105(29), 9988-9993 (2008).
24. Krupnick JG, Goodman OB Jr, Keen JH, Benovic JL. Arrestin/clathrin interaction. Localization of the clathrin binding domain of nonvisual arrestins to the carboxy terminus. J. Biol. Chem. 272(23), 15011-15016 (1997). (Pubitemid 27251777)
25. Goodman OB Jr, Krupnick JG, Santini F et al. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 383(6599), 447-450 (1996). (Pubitemid 26330835)
26. Laporte SA, Oakley RH, Zhang J et al. The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc. Natl Acad. Sci. USA 96(7), 3712-3717 (1999). (Pubitemid 29168975)
27. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Beta-arrestins and cell signaling. Annu. Rev. Physiol. 69, 483-510 (2007).
28. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J. Biol. Chem. 274(18), 12670-12674 (1999).
29. Rathz DA, Gregory KN, Fang Y, Brown KM, Liggett SB. Hierarchy of polymorphic variation and desensitization permutations relative to beta 1-and beta 2-adrenergic receptor signaling. J. Biol. Chem. 278(12), 10784-10789 (2003). (Pubitemid 36800351)
30. Mialet Perez J, Rathz DA, Petrashevskaya NN et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat. Med. 9(10), 1300-1305 (2003). (Pubitemid 37279854)
31. Liggett SB, Mialet-Perez J, Thaneemit-Chen S et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc. Natl Acad. Sci. USA 103(30), 11288-11293 (2006). (Pubitemid 44156511)
32. Brodde OE. Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol. Ther. 117(1), 1-29 (2008).
33. Leineweber K, Bogedain P, Wolf C et al. In patients chronically treated with metoprolol, the demand of inotropic catecholamine support after coronary artery bypass grafting is determined by the Arg389Gly-beta 1-adrenoceptor polymorphism. Naunyn Schmiedebergs Arch. Pharmacol. 375(5), 303-309 (2007). (Pubitemid 46945336)
34. Sandilands AJ, O'Shaughnessy KM, Brown MJ. Greater inotropic and cyclic AMP responses evoked by noradrenaline through Arg389 beta 1-adrenoceptors versus Gly389 beta 1-adrenoceptors in isolated human atrial myocardium. Br. J. Pharmacol. 138(2), 386-392 (2003). (Pubitemid 36188600)
35. Büscher R, Belger H, Eilmes KJ et al. Invivo studies do not support a major functional role for the Gly389Arg beta 1-adrenoceptor polymorphism in humans. Pharmacogenetics 11(3), 199-205 (2001). (Pubitemid 32319869)
36. O'Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin. Sci. (Lond). 99(3), 233-238 (2000).
37. Rathz DA, Brown KM, Kramer LA, Liggett SB. Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J. Cardiovasc. Pharmacol. 39(2), 155-160 (2002). (Pubitemid 34093534)
38. Sandilands A, Yeo G, Brown MJ, O'Shaughnessy KM. Functional responses of human beta1 adrenoceptors with defined haplotypes for the common 389RG and 49SG polymorphisms. Pharmacogenetics 14(6), 343-349 (2004). (Pubitemid 38813688)
39. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33(32), 9414-9419 (1994). (Pubitemid 24272896)
40. Ahles A, Rochais F, Frambach T, Bünemann M, Engelhardt S. A polymorphism-specific "memory" mechanism in the {beta}2-adrenergic receptor. Sci. Signal. 4(185), ra53 (2011).
41. Onorato JJ, Palczewski K, Regan JW, Caron MG, Lefkowitz RJ, and Benovic JL. Role of acidic amino acids in peptide substrates of the beta-adrenergic receptor kinase and rhodopsin kinase. Biochemistry 30(21), 5118-5125 (1991).
42. Small KM, Brown KM, Forbes SL, Liggett SB. Polymorphic deletion of three intracellular acidic residues of the alpha2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization. J. Biol. Chem. 276(7), 4917-4922 (2001).
43. Nguyen K, Kassimatis T, Lymperopoulos A. Impaired desensitization of a human polymorphic a2B-adrenergic receptor variant enhances its sympatho-inhibitory activity in chromaffin cells. Cell Commun. Signal. 9(1), 5 (2011).
44. Snapir A, Mikkelsson J, Perola M, Penttila A, Scheinin M, Karhunen PJ. Variation in the alpha2B-adrenoceptor gene as a risk factor for prehospital fatal myocardial infarction and sudden cardiac death. J. Am. Coll. Cardiol. 41(2), 190-194 (2003). (Pubitemid 36092182)
45. Laukkanen JA, Makikallio TH, Kauhanen J, Kurl S. Insertion/deletion polymorphism in alpha2-adrenergic receptor gene is a genetic risk factor for sudden cardiac death. Am. Heart J. 158(4), 615-621 (2009).
46. Von Wowern F, Bengtsson K, Lindblad U, Rastam L, Melander O. Functional variant in the (alpha)2B adrenoceptor gene, a positional candidate on chromosome 2, associates with hypertension. Hypertension 43(3), 592-597 (2004). (Pubitemid 38282433)
47. Ohlin B, Berglund G, Nilsson PM, Melander O. Job strain, decision latitude and alpha2B-adrenergic receptor polymorphism significantly interact, and associate with high blood pressures in men. J. Hypertension 25(8), 1613-1619 (2007). (Pubitemid 47056567)
48. Laaksonen DE, Siitonen N, Lindstrom J et al. Physical activity, diet and incident diabetes in relation to an ADRA2B polymorphism. Med. Sci. Sports Exerc. 39(2), 2227-2232 (2007).
49. Siitonen N, Lindstom J, Eriksson J et al. Association between a deletion/insertion polymorphism in the alpha2B-adrenergic receptor gene and insulin secretion and Type 2 diabetes. Diabetologia 47(8), 1416-1424 (2004). (Pubitemid 39232428)
50. Rotondo A, Nielsen DA, Nakhai B, Hulihan-Giblin B, Bolos A, Goldman D. Agonist-promoted down-regulation and functional desensitization in two naturally occurring variants of the human serotonin1A receptor. Neuropsychopharmacology 17(1), 18-26 (1997). (Pubitemid 27259709)
51. Arranz MJ, Munro J, Owen MJ et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol. Psychiatry 3(1), 61-66 (1998). (Pubitemid 28045186)
52. Rosenthal W, Seibold A, Antaramian A et al. Mutations in the vasopressin V2 receptor gene in families with nephrogenic diabetes insipidus and functional expression of the Q-2 mutant. Cell Mol. Biol. 40(3), 429-436 (1994).
53. Barak LS, Oakley RH, Laporte SA, Caron MG. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc. Natl Acad. Sci. USA 98(1), 93-98 (2001). (Pubitemid 32095869)
54. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J. Biol. Chem. 276(5), 3130-3137 (2001).
55. Koch T, Kroslak T, Averbeck M et al. Allelic variation S268P of the human mu-opioid receptor affects both desensitization and G protein coupling. Mol. Pharmacol. 58(2), 328-334 (2000). (Pubitemid 30497476)
56. Kunapuli P, Benovic JL. Cloning and expression of GRK5: a member of the G protein-coupled receptor kinase family. Proc. Natl Acad. Sci. USA 90(12), 5588-5592 (1993). (Pubitemid 23176206)
57. Premont RT, Koch WJ, Inglese J, Lefkowitz RJ. Identification, purification, and characterization of GRK5, a member of the family of G protein-coupled receptor kinases. J. Biol. Chem. 269(9), 6832-6841 (1994). (Pubitemid 24191077)
58. Liggett SB, Cresci S, Kelly RJ et al. A GRK5 polymorphism that inhibits b-adrenergic receptor signaling is protective in heart failure. Nat. Med. 14(5), 510-517 (2008). (Pubitemid 351655214)
59. Pronin AN, Satpaev DK, Slepak VZ, Benovic JL. Regulation of G protein-coupled receptor kinases by calmodulin and localization of the calmodulin binding domain. J. Biol. Chem. 272(29), 18273-18280 (1997). (Pubitemid 27306417)
60. Wang WC, Mihlbachler KA, Bleecker ER, Weiss ST, Liggett SB. A polymorphism of G-protein coupled receptor kinase-5 alters agonist-promoted desensitization of b2-adrenergic receptors. Pharmacogenet. Genomics 18(8), 729-732 (2008).
61. Freeman JL, De La Cruz EM, Pollard TD, Lefkowitz RJ, Pitcher JA. Regulation of G protein-coupled receptor kinase 5(GRK5) by actin. J. Biol. Chem. 273(32), 20653-20657 (1998). (Pubitemid 28377637)
62. Sallese M, Iacovelli L, Cumashi A, Capobianco L, Cuomo L, De Blasi A. Regulation of G protein-coupled receptor kinase subtypes by calcium sensor proteins. Biochim. Biophys. Acta 1498(2-3), 112-121 (2000).
63. Chen EP, Bittner HB, Akhter SA, Koch WJ, Davis RD. Myocardial function in hearts with transgenic overexpression of the G protein-coupled receptor kinase 5. Ann. Thorac. Surg. 71(4), 1320-1324 (2001). (Pubitemid 32328697)
64. Matkovich SJ, Diwan A, Klanke JL et al. Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ. Res. 99(9), 996-1003 (2006). (Pubitemid 44657803)
65. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353(9169), 2001-2007 (1999).
66. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 334(21), 1349-1355 (1996). (Pubitemid 26152713)
67. Fauchier L, Pierre B, de Labriolle A, Babuty D. Comparison of the beneficial effect of beta-blockers on mortality in patients with ischaemic or non-ischaemic systolic heart failure: a meta-analysis of randomised controlled trials. Eur. J. Heart Fail. 9(11), 1136-1139 (2007). (Pubitemid 47633317)
68. Yancy CW. The role of race in heart failure therapy. Curr. Cardiol. Rep. 4(3), 218-225 (2002).
69. Cresci S, Kelly RJ, Cappola TP et al. Clinical and genetic modifiers of long-term survival in heart failure. J. Am. Coll. Cardiol. 54(5), 432-444 (2009).
70. Lyon AR, Rees PS, Prasad S, Poole-Wilson PA, Harding SE. Stress (Takotsubo) cardiomyopathy: a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat. Clin. Pract. Cardiovasc. Med. 5(1), 22-29 (2008).
71. Wittstein IS, Thiemann DR, Lima JA et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N. Engl. J. Med. 352(6), 539-548 (2005). (Pubitemid 40204667)
72. Spinelli L, Trimarco V, Di MS, Marino M, Iaccarino G, Trimarco B. L41Q polymorphism of the G protein coupled receptor kinase 5 is associated with left ventricular apical ballooning syndrome. Eur. J. Heart Fail. 12(1), 13-16 (2010).
73. Gildea JJ, Shah I, Weiss R et al. HK-2 human renal proximal tubule cells as a model for G protein-coupled receptor kinase type 4-mediated dopamine 1 receptor uncoupling. Hypertension 56(5), 505-511 (2010).
74. Felder RA, Sanada H, Xu J et al. G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc. Natl Acad. Sci. USA 99(6), 3872-3877 (2002). (Pubitemid 34252198)
75. Lohmueller KE, Wong LJ, Mauney MM et al. Patterns of genetic variation in the hypertension candidate gene GRK4. ethnic variation and haplotype structure. Ann. Hum. Genet. 70(Pt 1), 27-41 (2006). (Pubitemid 43355559)
76. Sanada H, Yatabe J, Midorikawa S et al. Single-nucleotide polymorphisms for diagnosis of salt-sensitive hypertension. Clin. Chem. 52(3), 352-360 (2006).
77. Speirs HJ, Katyk K, Kumar NN, Benjafield AV, Wang WY, Morris BJ. Association of G-protein-coupled receptor kinase 4 haplotypes, but not HSD3B1 or PTP1B polymorphisms, with essential hypertension. J. Hypertens. 22(5), 931-936 (2004). (Pubitemid 38680467)
78. Gu D, Su S, Ge D et al. Association study with 33 single-nucleotide polymorphisms in 11 candidate genes for hypertension in Chinese. Hypertension 47(6), 1147-1154 (2006). (Pubitemid 44289172)
79. Wang Y, Li B, Zhao W et al. Association study of G protein-coupled receptor kinase 4 gene variants with essential hypertension in northern Han Chinese. Ann. Hum. Genet. 70(Pt 6), 778-783 (2006). (Pubitemid 44530641)
80. Staessen JA, Kuznetsova T, Zhang H et al. Blood pressure and renal sodium handling in relation to genetic variation in the DRD1 promoter and GRK4. Hypertension 51(6), 1643-1650 (2008).
81. Bhatnagar V, O'Connor DT, Brophy VH et al. G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am. J. Hypertens. 22(3), 332-338 (2009).
82. Wilbanks AM, Laporte SA, Bohn LM, Barak LS, Caron MG. Apparent loss-of-function mutant GPCRs revealed as constitutively desensitized receptors. Biochemistry 41(40), 11981-11989 (2002).
83. Gether U, Kobilka BK. G protein-coupled receptors. II. Mechanism of agonist activation. J. Biol. Chem. 273(29), 17979-17982 (1998).
84. Kobilka BK. Structural insights into adrenergic receptor function and pharmacology. Trends Pharmacol. Sci. 32(4), 213-218 (2011).
85. Apfelstedt-Sylla E, Kunisch M, Horn M et al. Ocular findings in a family with autosomal dominant retinitis pigmentosa and a frameshift mutation altering the carboxyl terminal sequence of rhodopsin. Br. J. Ophthalmol. 77(8), 495-501 (1993). (Pubitemid 23236725)
86. Kim RY, al-Maghtheh M, Fitzke FW et al. Dominant retinitis pigmentosa associated with two rhodopsin gene mutations. Leu-40-Arg and an insertion disrupting the 5́-splice junction of exon 5. Arch. Ophthalmol. 111(11), 1518-1524 (1993). (Pubitemid 23331987)
87. Restagno G, Maghtheh M, Bhattacharya S et al. A large deletion at the 3́ end of the rhodopsin gene in an Italian family with a diffuse form of autosomal dominant retinitis pigmentosa. Hum. Mol. Genet. 2(2), 207-208 (1993). (Pubitemid 23075663)
88. Cideciyan AV, Zhao X, Nielsen L, Khani SC, Jacobson SG, Palczewski K. Null mutation in the rhodopsin kinase gene slows recovery kinetics of rod and cone phototransduction in man. Proc. Natl Acad. Sci. USA 95(1), 328-333 (1998). (Pubitemid 28103953)
89. Yamamoto S, Sippel KC, Berson EL, Dryja TP. Defects in the rhodopsin kinase gene in the Oguchi form of stationary night blindness. Nat. Genet. 15(2), 175-178 (1997). (Pubitemid 27061637)
90. Fuchs S, Nakazawa M, Maw M, Tamai M, Oguchi Y, Gal A. A homozygous 1-base pair deletion in the arrestin gene is a frequent cause of Oguchi disease in Japanese. Nat. Genet. 10(3), 360-362 (1995).
91. Yamaki K, Tsuda M, Shinohara T. The sequence of human retinal S-antigen reveals similarities with alpha-transducin. FEBS Lett. 234(1), 39-43 (1988).
92. Palczewski K, Rispoli G, Detwiler PB. The influence of arrestin (48K protein) and rhodopsin kinase on visual transduction. Neuron 8(1), 117-126 (1992).
93. Nakamura M, Yamamoto S, Okada M, Ito S, Tano Y, Miyake Y. Novel mutations in the arrestin gene and associated clinical features in Japanese patients with Oguchi's disease. Ophthalmology 111(7), 1410-1414 (2004). (Pubitemid 38844845)
94. Sippel KC, DeStefano JD, Berson EL, Dryja TP. Evaluation of the human arrestin gene in patients with retinitis pigmentosa and stationary night blindness. Invest. Ophthalmol. Vis. Sci. 39(3), 665-670 (1998). (Pubitemid 28110705)
95. Nakazawa M, Wada Y, Tamai M. Arrestin gene mutations in autosomal recessive retinitis pigmentosa. Arch. Ophthalmol. 116(4), 498-501 (1998). (Pubitemid 28169751)
96. Belmonte SL, Blaxall BC. G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. Circ. Res. 109(3), 309-319 (2011).
97. Rengo G, Lymperopoulos A, Leosco D, Koch WJ. GRK2 as a novel gene therapy target in heart failure. J. Mol. Cell. Cardiol. 50(5), 785-792 (2011).
98. Lymperopoulos A, Rengo G, Funakoshi H, Eckhart AD, Koch WJ. Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat. Med. 13(3), 315-323 (2007). (Pubitemid 46376685)
99. Lymperopoulos A, Rengo G, Koch WJ. Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. Trends Mol. Med. 13(12), 503-511 (2007). (Pubitemid 350123195)
100. Iaccarino G, Barbato E, Cipolletta E et al. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur. Heart J. 26(17), 1752-1758 (2005). (Pubitemid 41219848)
101. Hata JA, Williams ML, Schroder JN et al. Lymphocyte levels of GRK2 (bARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved b-adrenergic signaling after mechanical unloading. J. Card. Fail. 12(5), 360-368 (2006). (Pubitemid 43817584)
102. Bonita RE, Raake PW, Otis NJ et al. Dynamic changes in lymphocyte GRK2 levels in cardiac transplant patients: a biomarker for left ventricular function. Clin. Transl. Sci. 3(1), 14-18 (2010).
103. Choi DJ, Koch WJ, Hunter JJ, Rockman HA. Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase. J. Biol. Chem. 272(27), 17223-17229 (1997). (Pubitemid 27289837)
104. Ungerer M, Kessebohm K, Kronsbein K, Lohse MJ, Richardt G. Activation of beta-adrenergic receptor kinase during myocardial ischemia. Circ. Res. 79(3), 455-460 (1996). (Pubitemid 26276906)
105. Gros R, Benovic JL, Tan CM, Feldman RD. G-protein-coupled receptor kinase activity is increased in hypertension. J. Clin. Invest. 99(9), 2087-2093 (1997). (Pubitemid 27203764)
106. Leosco D, Rengo G, Iaccarino G et al. Exercise training and beta-blocker treatment ameliorate age-dependent impairment of beta-adrenergic receptor signaling and enhance cardiac responsiveness to adrenergic stimulation. Am. J. Physiol. Heart Circ. Physiol. 293(3), H1596-H1603 (2007). (Pubitemid 47367205)
107. Luan B, Zhao J, Wu H et al. Deficiency of a beta-arrestin-2 signal complex contributes to insulin resistance. Nature 457(7233), 1146-1149 (2009).
108. Li TT, Alemayehu M, Aziziyeh AI et al. Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol. Cancer Res. 7(7), 1064-1077 (2009).
109. Iaccarino G, Tomhave ED, Lefkowitz RJ, Koch WJ. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by b-adrenergic receptor stimulation and blockade. Circulation 98(17), 1783-1789 (1998). (Pubitemid 28492500)
110. Iaccarino G, Keys JR, Rapacciuolo A et al. Regulation of myocardial betaARK1 expression in catecholamine-induced cardiac hypertrophy in transgenic mice overexpressing alpha1B-adrenergic receptors. J. Am. Coll. Cardiol. 38(2), 534-540 (2001). (Pubitemid 32721785)
111. Rengo G, Lymperopoulos A, Zincarelli C et al. Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 119(1), 89-98 (2009).
112. Rengo G, Leosco D, Zincarelli C et al. Adrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failure. Am. J. Physiol. Heart Circ. Physiol. 298(6), H2032-H2038 (2010).
113. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Soltys S, Koch WJ. An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc. Natl Acad. Sci. USA 106(14), 5825-5830 (2009).
114. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Koch WJ. Adrenal Beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. J. Am. Coll. Cardiol. 57(3), 356-365 (2011).
115. Lymperopoulos A, Rengo G, Magafa V, Cordopatis P, Koch WJ. Biased agonism/antagonism of sartans and angiotensin II analogs for angiotensin II type 1 receptor-induced, b-arrestin-dependent aldosterone production in heart failure. Circulation 122(Suppl. 2), Abstract 10263, 2010 American Heart Association (AHA) Scientific Sessions 2010, Chicago, IL, USA, 13-17 November 2010.
116. Williams GH, Fisher ND, Hunt SC, Jeunemaitre X, Hopkins PN, Hollenberg NK. Effects of gender and genotype on the phenotypic expression of nonmodulating essential hypertension. Kidney Int. 57(4), 1404-1407 (2000). (Pubitemid 30207898)
117. Penela P, Murga C, Ribas C, Lafarga V, Mayor F Jr. The complex G protein-coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets. J. Pharmacol. 160(4), 821-832 (2010).
118. Penn RB, Pronin AN, Benovic JL. Regulation of G Protein-Coupled Receptor Kinases. Trends Cardiovasc. Med. 10(2), 81-89 (2000). (Pubitemid 32012684)
119. Ramos-Ruiz R, Penela P, Penn RB, Mayor F Jr. Analysis of the human G protein-coupled receptor kinase 2 (GRK2) gene promoter: regulation by signal transduction systems in aortic smooth muscle cells. Circulation 101(17), 2083-2089 (2000). (Pubitemid 30233173)
120. Zhou X, Barrett TB, Kelsoe JR. Promoter variant in the GRK3 gene associated with bipolar disorder alters gene expression. Biol. Psychiatry 64(2), 104-110 (2008).
121. Yu SY, Takahashi S, Arinami T et al. Mutation screening and association study of the beta-adrenergic receptor kinase 2 gene in schizophrenia families. Psychiatry Res. 125(2), 95-104 (2004). (Pubitemid 38299472)
122. Guindalini C, Collier D, Laranjeira R et al. Association analysis of GRK3 gene promoter variants in cocaine abuse. Psychiatr. Genet. 17(4), 239-242 (2007). (Pubitemid 47051908)
123. Ma L, Pei G. Beta-arrestin signaling and regulation of transcription. J. Cell Sci. 120(Pt 2), 213-218 (2007).